Atopic Dermatitis: New Targets and Emerging Systemic Therapies

Atopic dermatitis (AD) is a chronic inflammatory skin disease, driven by barrier and immune dysregulation, which causes significant impairment in quality of life. The introduction of biologics and oral small molecules has substantially improved treatment outcomes. However, achieving complete and durable clinical clearance for most patients remains challenging, and concerns related to long-term safety and healthcare burden persist as key unmet needs. These limitations have catalyzed a new phase of therapeutic innovation in AD. Next-generation biologics targeting type 2 cytokines are being refined through advances in antibody bioengineering, including high binding affinity and fragment crystallizable modification, with the aim of enhancing efficacy while achieving extended dosing intervals. In parallel, bispecific and multispecific antibodies, designed to simultaneously engage multiple epitopes on the same or distinct antigens, are increasingly being evaluated in inflammatory skin diseases after initial development in oncology, offering the potential for synergistic immunomodulatory effects. This evolving landscape is further complemented by evidence from T-cell rebalancing strategies that showed durable off-treatment responses, positioning these approaches as potential game changers in long-term disease control. Lastly, emerging oral small-molecule agents that inhibit intracellular signaling downstream of multiple cytokines are supported by favorable safety profiles in early-phase trials. Overall, this review synthesizes current translational and clinical advances shaping the evolving pipeline, highlighting how both novel ways of modulating established pathways and the identification of new targets may transform the future management of AD.